Skip to main content
RemeGen Co., Ltd. logo

RemeGen Co., Ltd. — Investor Relations & Filings

Ticker · 9995 ISIN · CNE1000048G6 LEI · 300300M9HCX4TFAD4I10 HKEX Manufacturing
Open in API
Filings indexed 1,624 across all filing types
Latest filing 2025-06-17 Regulatory Filings
Country CN China
Listing HKEX 9995

About RemeGen Co., Ltd.

http://www.remegen.com

RemeGen Co., Ltd. is a biopharmaceutical company dedicated to the discovery, development, production, and commercialization of innovative biological drugs. The company focuses on creating first-in-class and best-in-class therapeutics to address significant unmet clinical needs, particularly in the critical therapeutic areas of autoimmune diseases, oncology, and ophthalmology. RemeGen utilizes proprietary technology platforms capable of discovering, screening, and developing new molecules and efficiently optimizing production processes. Its pipeline includes a series of innovative biologics, such as Telitacicept, and features 8 clinical pipelines, over 40 clinical trials, and more than 600 patent applications, demonstrating a strong commitment to R&D and innovation in biopharmaceuticals.

Recent filings

Filing Released Lang Actions
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2025-06-17 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2025-06-13 English
PROXY FORM FOR ANNUAL GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 85% confidence The document is the full text of a proxy form for the Annual General Meeting, providing shareholders with voting instructions and appointment of proxies. This matches the definition of Proxy Solicitation & Information Statement, which includes materials sent to shareholders requesting votes for meetings.
2025-06-05 English
NOTICE OF ANNUAL GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 88% confidence The document is a “Notice of Annual General Meeting” sent to shareholders detailing meeting logistics, resolutions to be voted on, proxy appointment instructions, and explanatory notes. It is not the AGM presentation/material (AGM-R) nor the voting results. Instead, it is a solicitation of proxies and information to shareholders to request votes at the upcoming meeting, fitting the Proxy Solicitation & Information Statement category.
2025-06-05 English
RENEWAL OF GENERAL MANDATES TO ISSUE NEW SHARES AND REPURCHASE SHARES PROPOSED APPOINTMENT OF NEW AUDITOR PROPOSED RE-ELECTION OF DIRECTORS AND NOTICE OF ANNUAL GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 88% confidence The document is a lengthy shareholder circular issued by Overseas Chinese Town (Asia) Holdings Limited ahead of its Annual General Meeting. It includes detailed explanatory statements for resolutions (renewal of mandates, auditor appointment, director re-elections), biographies of directors, and the notice of the AGM along with proxy information. This corresponds to materials sent to shareholders to request votes and provide information for a general meeting. Therefore, it is classified as a Proxy Solicitation & Information Statement (PSI).
2025-06-05 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2025
Share Issue/Capital Change Classification · 85% confidence The document is a HKEX FF301 “Monthly Return for Equity Issuer” detailing movements in authorised and issued share capital, placements/subscriptions, share option grants, and other capital changes for the month ended 31 May 2025. It is not an annual or interim report, earnings release, management discussion, nor simply a publication announcement; it specifically reports share issues and other capital changes. Therefore it best fits the “Share Issue/Capital Change” category (SHA).
2025-06-04 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.